Outlook Therapeutics, Inc. (OTLK) Research

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Market snapshot

Symbol
OTLK
Price
$1.58
Day change
-4.24%
Market cap
$65.0M
P/E ratio
-2.12x
52-week range
0.161-3.39
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$1.00

Recent news

  • Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time

    Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the company announced the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA.

  • Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA

    Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration granted its appeal following the Formal Dispute Resolution process for ONS-5010 or LYTENAVA (bevacizumab-vikg).

Peer companies

  • Coeptis Therapeutics, Inc. (COEP)
  • Cue Biopharma, Inc. (CUE)
  • Equillium, Inc. (EQ)
  • Werewolf Therapeutics, Inc. (HOWL)
  • IO Biotech, Inc. (IOBT)
  • Century Therapeutics, Inc. (IPSC)
  • Medicus Pharma Ltd. Common Stock (MDCX)
  • NRx Pharmaceuticals, Inc. (NRXP)

Recent insider activity

  • Haddadin Yezan Munther — P-Purchase (29000 shares) on 2026-06-02
  • Sukhtian Ghiath M. — P-Purchase (8539709 shares) on 2026-05-28
  • Sukhtian Ghiath M. — P-Purchase (8571428 shares) on 2026-05-28
  • Sukhtian Ghiath M. — P-Purchase (3458571 shares) on 2026-05-28
  • Sukhtian Ghiath M. — H-ExpireLong (8571428 shares) on 2026-05-28

Open Outlook Therapeutics, Inc. (OTLK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.